Share on StockTwits

DexCom (NASDAQ:DXCM) has been given an average rating of “Hold” by the thirteen analysts that are covering the stock, Analyst Ratings.Net reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $41.00.

DexCom (NASDAQ:DXCM) traded down 0.82% on Wednesday, hitting $44.55. The stock had a trading volume of 58,685 shares. DexCom has a 52-week low of $25.49 and a 52-week high of $49.83. The stock has a 50-day moving average of $39.41 and a 200-day moving average of $38.83. The company’s market cap is $3.362 billion.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the prior year, the company posted ($0.14) earnings per share. The company’s quarterly revenue was up 64.2% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.32 earnings per share for the current fiscal year.

In other DexCom news, CEO Terrance H. Gregg sold 25,000 shares of the stock on the open market in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $44.24, for a total transaction of $1,106,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on DXCM shares. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.